Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 4Peritoneal Neoplasms 3Fallopian Tube Neoplasms 3Stomach Neoplasms 2Carcinoma 2Neoplasms, Glandular and Epithelial 1Neoplasms 1Ascites 1Adenocarcinoma 1

Interventions

Carboplatin 44Paclitaxel 42Cisplatin 20Topotecan 17Gemcitabine 16Docetaxel 13Bevacizumab 13liposomal doxorubicin 7olaparib 6Cyclophosphamide 6pembrolizumab 5Surgical Procedures, Operative 5Filgrastim 5Etoposide 5Drug Therapy 5Amifostine 5sargramostim 4oregovomab 4catumaxomab 4anlotinib 4Imatinib Mesylate 4Hyperthermic Intraperitoneal Chemotherapy 4rucaparib 3pegfilgrastim 3niraparib 3ixabepilone 3aldesleukin 3Standard of Care 3Peripheral Blood Stem Cell Transplantation 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Ovarian Epithelial × catumaxomab × Clear all
NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed
32 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01815528 2015-02-18

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Charite University, Berlin, Germany

Phase 2 Completed
2 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00563836 2012-10-03

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Neovii Biotech

Phase 2 Completed
41 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00377429 2012-07-19

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Neovii Biotech

Phase 2 Completed
47 enrolled 11 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡